Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently recruiting for a Phase 2a clinical study titled A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases. The study aims to evaluate the safety and tolerability of inebilizumab and blinatumomab in adults with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), conditions that are notoriously challenging to treat. This research is significant as it targets refractory cases, potentially offering new hope for patients with limited treatment options.
The interventions being tested are inebilizumab, administered via intravenous infusion, and blinatumomab, delivered through subcutaneous injection. Inebilizumab is being tested in two dosing regimens, while blinatumomab is being evaluated in three dosing levels across different subprotocols.
The study is designed as an open-label, non-randomized, sequential trial focusing on treatment. There is no masking involved, allowing for direct observation of the treatment effects.
The study began on July 16, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 6, 2025, indicating ongoing progress in the recruitment phase.
This clinical update could influence Amgen’s stock performance positively, as successful outcomes may enhance their portfolio in the autoimmune disease market. Investors should watch for developments, especially given the competitive landscape with other biotech firms exploring similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.